Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C22H17ClF3N9O2
CAS Number:
Molecular Weight:
531.88
UNSPSC Code:
51111800
NACRES:
NA.77
Product Name
S-217622, ≥98% (HPLC)
InChI
1S/C22H17ClF3N9O2/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24/h3-7,10H,8-9H2,1-2H3,(H,28,29,36)
InChI key
QMPBBNUOBOFBFS-UHFFFAOYSA-N
SMILES string
O=C1N/C(N(C(N1CC2=NN(C=N2)C)=O)CC3=CC(F)=C(F)C=C3F)=N\C4=CC5=CN(N=C5C=C4Cl)C
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
Orally available potent and selective noncovalent and nonpeptidic inhibitor of SARS-CoV-2 3C-like protease (3CLpro, or Mpro)
S-217622 is an orally available potent and selective noncovalent and nonpeptidic inhibitor of SARS-CoV-2 3C-like protease (3CLpro, or Mpro) that exhibits antiviral activity in vitro against varies variants of SARS-CoV-2 and other coronaviruses. S-217622 potently inhibits intrapulmonary replication of SARS-CoV-2 in mice.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Journal of medicinal chemistry, 65(9), 6499-6512 (2022)
S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2
Tyndall JDA
Journal of Medicinal Chemistry, 65(9), 6496-6498 (2022)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service